Figure 1.
(A) Investigator-assessed progression-free survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab; ITT, intention-to-treat; nab-Pac, nab-paclitaxel; NE, not estimable; PD-L1, programmed death-ligand 1.
(A) Investigator-assessed progression-free survival in Japanese patients (ITT) and (B) PD-L1–positive patients. Atezo, atezolizumab; ITT, intention-to-treat; nab-Pac, nab-paclitaxel; NE, not estimable; PD-L1, programmed death-ligand 1.